Volume 121, Issue 6 , Pages 1442-1447, June 2008
Preventive effect of hydrolyzed infant formulas persists until age 6 years: Long-term results from the German Infant Nutritional Intervention Study (GINI)
Background
The long-term effect of nutritional intervention with hydrolyzed infant formulas on allergy development has not been sufficiently evaluated.
Objective
We performed a follow–up of the German Infant Nutritional Intervention study until 6 years of life to investigate the long-term allergy-preventive effect of 3 hydrolyzed infant formulas compared with cow's milk formula (CMF) in a randomized, double-blind trial.
Methods
Between 1995 and 1998, 2252 newborns with atopic heredity were randomly assigned at birth to receive one of 4 blinded formulas: partially or extensively hydrolyzed whey formula, extensively hydrolyzed casein formula, or CMF as milk substitute for the first 4 months when breast-feeding was insufficient. The cohort was followed from birth until 6 years of age with yearly questionnaires. Outcomes were physician-diagnosed allergic diseases (atopic dermatitis, food allergy, allergic urticaria, asthma, and hay fever/allergic rhinitis). Log-binomial regression modeled with generalized estimation equations was used for the statistical analysis.
Results
In the intent-to-treat analysis the relative risk of a physician's diagnosis of allergic manifestation (AM) compared with CMF was 0.82 (95% CI, 0.70-0.96) for partially hydrolyzed whey formula, 0.90 (95% CI, 0.78-1.04) for extensively hydrolyzed whey formula, and 0.80 (95% CI, 0.69-0.93) for extensively hydrolyzed casein formula. The corresponding figures for atopic eczema were 0.79 (95% CI, 0.64-0.97), 0.92 (95% CI, 0.76-1.11), and 0.71 (95% CI, 0.58-0.88), respectively. In the per-protocol analysis all effects were stronger and significant. No significant effect on other AMs was found.
Conclusion
The data confirm a long-term allergy-preventive effect of hydrolyzed infant formulas on AM and atopic eczema until 6 years of age.
Key words: Birth cohort, long-term allergy prevention, hydrolysates, double-blind randomized trial
Abbreviations used: AM, Allergic manifestation, AD, Atopic dermatitis used synonymously to eczema according to the new nomenclature for reasons of continuity with previous articles by the GINI, CMF, Cow's milk formula, eHF-C, Extensively hydrolyzed casein formula, eHF-W, Extensively hydrolyzed whey formula, GINI, German Infant Nutritional Intervention, ITT, Intent-to-treat, pHF-W, Partially hydrolyzed whey formula, PP, Per-protocol
The German Infant Nutritional Intervention study was supported for the first 3 years by grants of the Federal Ministry for Education, Science, Research and Technology (Grant No. 01 EE 9401-4). The 6-year follow-up was partly funded by the Federal Ministry for Environment (IUF, FKZ 20462296) and by the GSF National Research Center for the Environment and Health.
Disclosure of potential conflict of interest: A. von Berg has served on the speakers' bureau for MSD, Nestlé, Novartis, and Aerocrine; has served as the principal investigator for Nestlé, Mead Johnson, GlaxoSmithKline, Aerocrine, Nycomed, MSD, Allergopharma, and ALK-Abelló; and has served as an expert witness for Aerocrine and Novartis. U. Krämer has received research support from the Deutsche gesetzliche Unfallversicherung and the Federal Ministry for Environment. E. Link has received research support from the Federal Ministry for Environment. S. Koletzko has received honoraria from Nestlé, Nutricia, and Hipp and has served as an investigator for Nestlé. D. Berdel has served on the speakers' bureau for MSD, Nestlé, and Wyeth. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(08)00765-3
doi:10.1016/j.jaci.2008.04.021
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 121, Issue 6 , Pages 1442-1447, June 2008

